Epizyme secures $32 million in financing

10/8/2009 | American City Business Journals

Epizyme, which makes drugs that block enzymes that appear to play a role in diseases such as cancer and inflammatory conditions, raised $32 million in a round of financing led by Bay City Capital. The funding will enable the biotech company to conduct "proof-of-concept studies" of its lead drug compounds, CEO Kazumi Shiosaki said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN